PHASE III TRIAL OF CRISNATOL MESYLATE VS BCNU IN BRAIN TUMOR PATIENTS

甲磺酸克瑞那醇 VS BCNU 在脑肿瘤患者中的 III 期试验

• 批准号: 6244935
• 负责人: STEVEN K GUDEMAN
• 金额: $ 1.34万
• 依托单位: UNIV OF NORTH CAROLINA CHAPEL HILL
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-01-06 至 1997-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6244935
• 关键词: antineoplastics; carmustine; clinical research; drug screening /evaluation; glioblastoma multiforme; human mortality; human subject; human therapy evaluation; neoplasm /cancer chemotherapy; neoplasm /cancer relapse /recurrence; neoplastic process

The primary objective is to determine whether Crisnatol Mesylate is superior to BCNU as measured by time to tumor recurrence or progression in patients with glioblastoma multiforme. A secondary objective is to determine whether Crisnatol is superior to BCNU as measured by overall survival in patients with glioblastoma multiforme.

主要目的是确定 Crisnatol Mesylate 是否是 以肿瘤复发或进展时间衡量，优于 BCNU 多形性胶质母细胞瘤患者。 次要目标是 确定 Crisnatol 是否优于 BCNU（按总体衡量） 多形性胶质母细胞瘤患者的生存率。